924 related articles for article (PubMed ID: 15862745)
1. Overcoming the immortality of tumour cells by telomere and telomerase based cancer therapeutics--current status and future prospects.
Kelland LR
Eur J Cancer; 2005 May; 41(7):971-9. PubMed ID: 15862745
[TBL] [Abstract][Full Text] [Related]
2. Targeting the limitless replicative potential of cancer: the telomerase/telomere pathway.
Kelland L
Clin Cancer Res; 2007 Sep; 13(17):4960-3. PubMed ID: 17785545
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological intervention strategies for affecting telomerase activity: future prospects to treat cancer and degenerative disease.
Tárkányi I; Aradi J
Biochimie; 2008 Jan; 90(1):156-72. PubMed ID: 17945408
[TBL] [Abstract][Full Text] [Related]
4. Pharmacodynamics of the G-quadruplex-stabilizing telomerase inhibitor 3,11-difluoro-6,8,13-trimethyl-8H-quino[4,3,2-kl]acridinium methosulfate (RHPS4) in vitro: activity in human tumor cells correlates with telomere length and can be enhanced, or antagonized, with cytotoxic agents.
Cookson JC; Dai F; Smith V; Heald RA; Laughton CA; Stevens MF; Burger AM
Mol Pharmacol; 2005 Dec; 68(6):1551-8. PubMed ID: 16150933
[TBL] [Abstract][Full Text] [Related]
5. Telomerase inhibition and telomere targeting in hematopoietic cancer cell lines with small non-nucleosidic synthetic compounds (BIBR1532).
El Daly H; Martens UM
Methods Mol Biol; 2007; 405():47-60. PubMed ID: 18369817
[TBL] [Abstract][Full Text] [Related]
6. Specific telomere dysfunction induced by GRN163L increases radiation sensitivity in breast cancer cells.
Gomez-Millan J; Goldblatt EM; Gryaznov SM; Mendonca MS; Herbert BS
Int J Radiat Oncol Biol Phys; 2007 Mar; 67(3):897-905. PubMed ID: 17175117
[TBL] [Abstract][Full Text] [Related]
7. [Inhibition of telomeres and telomerase. Seeking for new anticancer drugs].
Raymond E; Faivre S; Dieras V; Von Hoff D
Bull Cancer; 1997 Dec; 84(12):1123-33. PubMed ID: 9587365
[TBL] [Abstract][Full Text] [Related]
8. Telomerase inhibitors in cancer therapy: current status and future directions.
Incles CM; Schultes CM; Neidle S
Curr Opin Investig Drugs; 2003 Jun; 4(6):675-85. PubMed ID: 12901225
[TBL] [Abstract][Full Text] [Related]
9. Telomerase as an anti-cancer target: current status and future prospects.
Neidle S; Kelland LR
Anticancer Drug Des; 1999 Aug; 14(4):341-7. PubMed ID: 10625926
[TBL] [Abstract][Full Text] [Related]
10. Effect of telomere and telomerase interactive agents on human tumor and normal cell lines.
Rha SY; Izbicka E; Lawrence R; Davidson K; Sun D; Moyer MP; Roodman GD; Hurley L; Von Hoff D
Clin Cancer Res; 2000 Mar; 6(3):987-93. PubMed ID: 10741725
[TBL] [Abstract][Full Text] [Related]
11. Oligonucleotide N3'-->P5' phosphoramidates as efficient telomerase inhibitors.
Herbert BS; Pongracz K; Shay JW; Gryaznov SM
Oncogene; 2002 Jan; 21(4):638-42. PubMed ID: 11850790
[TBL] [Abstract][Full Text] [Related]
12. Telomerase inhibition, telomere shortening, cell growth suppression and induction of apoptosis by telomestatin in childhood neuroblastoma cells.
Binz N; Shalaby T; Rivera P; Shin-ya K; Grotzer MA
Eur J Cancer; 2005 Dec; 41(18):2873-81. PubMed ID: 16253503
[TBL] [Abstract][Full Text] [Related]
13. The level of telomere dysfunction determines the efficacy of telomerase-based therapeutics in a lung cancer cell line.
Pantic M; Zimmermann S; Waller CF; Martens UM
Int J Oncol; 2005 May; 26(5):1227-32. PubMed ID: 15809713
[TBL] [Abstract][Full Text] [Related]
14. Assembly of mutant-template telomerase RNA into catalytically active telomerase ribonucleoprotein that can act on telomeres is required for apoptosis and cell cycle arrest in human cancer cells.
Goldkorn A; Blackburn EH
Cancer Res; 2006 Jun; 66(11):5763-71. PubMed ID: 16740715
[TBL] [Abstract][Full Text] [Related]
15. Telomerase inhibition by an siRNA directed against hTERT leads to telomere attrition in HT29 cells.
de Souza Nascimento P; Alves G; Fiedler W
Oncol Rep; 2006 Aug; 16(2):423-8. PubMed ID: 16820926
[TBL] [Abstract][Full Text] [Related]
16. Telomerase template antagonist GRN163L disrupts telomere maintenance, tumor growth, and metastasis of breast cancer.
Hochreiter AE; Xiao H; Goldblatt EM; Gryaznov SM; Miller KD; Badve S; Sledge GW; Herbert BS
Clin Cancer Res; 2006 May; 12(10):3184-92. PubMed ID: 16707619
[TBL] [Abstract][Full Text] [Related]
17. Effects of a novel telomerase inhibitor, GRN163L, in human breast cancer.
Gellert GC; Dikmen ZG; Wright WE; Gryaznov S; Shay JW
Breast Cancer Res Treat; 2006 Mar; 96(1):73-81. PubMed ID: 16319992
[TBL] [Abstract][Full Text] [Related]
18. [siRNA targeting telomerase--effective tool in anti-cancer therapy?].
Rubiś B; Półrolniczak A; Rybczyńska M
Postepy Biochem; 2008; 54(4):384-92. PubMed ID: 19248585
[TBL] [Abstract][Full Text] [Related]
19. Telomerase- and alternative telomere lengthening-independent telomere stabilization in a metastasis-derived human non-small cell lung cancer cell line: effect of ectopic hTERT.
Brachner A; Sasgary S; Pirker C; Rodgarkia C; Mikula M; Mikulits W; Bergmeister H; Setinek U; Wieser M; Chin SF; Caldas C; Micksche M; Cerni C; Berger W
Cancer Res; 2006 Apr; 66(7):3584-92. PubMed ID: 16585183
[TBL] [Abstract][Full Text] [Related]
20. Telomerase antagonists GRN163 and GRN163L inhibit tumor growth and increase chemosensitivity of human hepatoma.
Djojosubroto MW; Chin AC; Go N; Schaetzlein S; Manns MP; Gryaznov S; Harley CB; Rudolph KL
Hepatology; 2005 Nov; 42(5):1127-36. PubMed ID: 16114043
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
